<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05380414</url>
  </required_header>
  <id_info>
    <org_study_id>ET21-399 GENOPANC</org_study_id>
    <nct_id>NCT05380414</nct_id>
  </id_info>
  <brief_title>Profiling Program of Advanced/Metastatic Pancreatic Cancer Patients</brief_title>
  <official_title>A Single-center, Prospective Profiling Program of Advanced/Metastatic Pancreatic Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposal is to implement a molecular screening program for advanced/metastatic pancreatic&#xD;
      cancer patients before the initiation of 1st line treatment in order to allow a better&#xD;
      selection of patients for rationale personalized medicine with targeted agents and/or&#xD;
      combination involving a chemotherapy backbone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2022</start_date>
  <completion_date type="Anticipated">September 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with at least one actionable alteration defined as an alteration shown to predict for sensitivity to a drug FDA/EMA approved for use in another cancer type, or a relevant alteration for inclusion in a clinical trial.</measure>
    <time_frame>At the end of study (5 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from ICF signature to day 1 of next line of therapy</measure>
    <time_frame>At day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients initiating a targeted therapy according to this molecular screening program with type of therapy initiated</measure>
    <time_frame>At the end of study (5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response (BoR)</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR)</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Metastatic Pancreatic Cancer</condition>
  <condition>Advanced Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Metastatic/advanced PDAC Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tumor samples</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tumor samples (archival FFPE) and blood samples</intervention_name>
    <description>Molecular screening</description>
    <arm_group_label>Metastatic/advanced PDAC Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patient &gt; 18 years&#xD;
&#xD;
          -  metastatic or advanced PDAC&#xD;
&#xD;
          -  Patient pretreated with no more than one prior systemic chemotherapy for&#xD;
             metastatic/advanced disease (radiotherapy is not counted as a line of therapy).&#xD;
&#xD;
          -  Availability of an archival representative FFPE tumor sample from primary tumor&#xD;
             (surgery or diagnostic biopsy) and/or from metastatic lesion if metastatic disease at&#xD;
             initial diagnosis with associated pathology report from an archival tumor block.&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  PS score 0 or 1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Curative therapy available&#xD;
&#xD;
          -  Any condition contraindicated with blood sampling procedures required by the protocol.&#xD;
&#xD;
          -  Known additional malignancy that is progressing or requires active treatment.&#xD;
             Exceptions include adequately treated basal cell carcinoma of the skin, squamous cell&#xD;
             carcinoma of the skin, or in situ cervical cancer.&#xD;
&#xD;
          -  Any psychological, familial, geographic or social situation, according to the judgment&#xD;
             of investigator, potentially preventing the provision of informed consent or&#xD;
             compliance to study procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe CASSIER, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe CASSIER, MD, PhD</last_name>
    <phone>0426556835</phone>
    <email>philippe.cassier@lyon.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe CASSIER, MD, PhD</last_name>
      <phone>0426556835</phone>
      <email>philippe.cassier@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2022</verification_date>
  <study_first_submitted>May 10, 2022</study_first_submitted>
  <study_first_submitted_qc>May 16, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2022</study_first_posted>
  <last_update_submitted>July 21, 2022</last_update_submitted>
  <last_update_submitted_qc>July 21, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Molecular screening</keyword>
  <keyword>Genomic profiles</keyword>
  <keyword>Transcriptomic profiles</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

